Israeli biotech firm Pluri has entered into an exclusive collaboration with Ukrainian umbilical cord blood bank Hemafund to develop an emergency response to radiation sickness. Pluri's placenta-based cell therapy, PLX-R18, will be stockpiled and distributed as a potential treatment for life-threatening radiation sickness. The therapy stimulates and regenerates the production of all three types of blood cells produced in the bone marrow. Pluri and Hemafund will also seek to advance clinical trials and obtain necessary regulatory approvals. The collaboration is expected to potentially generate over $100 million in value for both parties.